Locations:
SearchIndividualized treatment summaries and survivorship care plans impact the survivorship knowledge and treatment distress of hematopoietic cell transplant survivors, according to a study presented at ASH 2017 and led by Navneet Majhail, MD, MS, Director of Cleveland Clinic Cancer Center’s Blood and Marrow Transplant Program.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Watch Dr. Majhail discuss the study design and results below:
Video content: This video is available to watch online.
View video online (https://www.youtube.com/embed/d7pfCJsetwc?feature=oembed)
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients